Дисертації з теми "Localized Drug Delivery System"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 дисертацій для дослідження на тему "Localized Drug Delivery System".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте дисертації для різних дисциплін та оформлюйте правильно вашу бібліографію.
Rodriguez, Lidia Betsabe. "Controlled Release System for Localized and Sustained Drug Delivery Applications." University of Toledo / OhioLINK, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=toledo1365107103.
Повний текст джерелаFalahat, Rana. "Tunable Nano-Delivery System for Cancer Treatment: A New Approach for Targeted Localized Drug Delivery." Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6234.
Повний текст джерелаRodríguez, Escalona Gabriela de Jesús. "DEVELOPMENT OF CONTROLLED DRUG DELIVERY SYSTEMS OF POLYMERIC NANOMEDICINES ASSOCIATED TO SCAFFOLDS FOR TISSUE REGENERATION." Doctoral thesis, Universitat Politècnica de València, 2016. http://hdl.handle.net/10251/63231.
Повний текст джерела[ES] Actualmente, una de las mayores preocupaciones que permanentemente laman la atención de los principales sectores de la sociedad humana es la salud. La ciencia médica moderna está comprometida no solo con suministrar tratamientos adecuados, sino más bien ofrecer soluciones efectivas y específicas para cada tipo de enfermedad o patología humana. En este sentido, estrategias innovadoras como la ingeniería de tejidos o la medicina regenerativa, los sistemas de liberación controlada de fármacos y las nanomedicinas, surgen como buenas alternativas para abordar situaciones difíciles de resolver aplicando los tratamientos y estrategias terapéuticas convencionales, como es el caso cuando se hace necesario reemplazar tejidos o incluso órganos dañados por algún traumatismo o enfermedad. Concretamente, el presente trabajo de investigación tiene por objetivo principal diseñar un sistema combinado para la liberación controlada, estable y localizada de agentes terapéuticos que sean capaces de ejercer su efecto de forma selectiva sobre la zona que amerita el tratamiento. Este constructo tendrá la versatilidad suficiente como para poder adaptarse a casi cualquier tipo de tratamiento, desde el cáncer hasta la regeneración de tejido, siempre que el requisito clave del tratamiento sea la necesidad de suministrar el tratamiento de manera localizada, estable y controlada. Para efectos de facilitar la compresión y el diseño del sistema se escogió para la prueba de concepto materiales y fármacos asociados a la regeneración de tejidos, como tratamiento para casos de heridas crónicas. El sistema en cuestión está constituido por tres elementos principales: 1) El primer elemento son los conjugados poliméricos de agentes terapéuticos que contribuirán a aumentar la selectividad de la acción terapéutica del fármaco, así como también a mejora la estabilidad, biodisponibilidad y biocompatibilidad de los mismos. En caso de que el fármaco sea hidrofóbico, la conjugación contribuye a aumentar su solubilidad en agua, y en el caso de usar proteínas como agentes terapéuticos, la conjugación contribuye a disminuir la respuesta inmunológica del cuerpo incrementando las posibilidad de éxito del tratamiento. 2) El segundo elemento son micropartículas poliméricas biodegradables, que en este caso actúan con agentes de encapsulación para los conjugados poliméricos, permitiendo así contar con un segundo punto de control en la cinética de liberación de los agentes terapéuticos. Simultáneamente, las micropartículas también cumplen un papel de modificador de la textura del constructo final, adjudicándole propiedades mecánica y fisicoquímicas que contribuyen a mejorar las propiedades biológicas del material final, como son la afinidad, la adhesión y la proliferación celular. 3) El tercer elemento consiste en una membrana polimérica biodegradable nanoporosa hecha por electrospinning, que constituyen el elemento unificados del sistema, aporta manejabilidad al constructo y es en sí mismo el último punto de control en la cinética de liberación del agente terapéutico. Este último debe ser biocompatible y estable en condiciones ambientales, puesto que probablemente este expuesto al ambiente mientras protege la herida, en el caso concreto de este tipo de aplicación. Estos tres elementos, que en sí mismos constituyen sistemas complejos por separado, se han combinado sistemáticamente para alcanzar una relación sinérgica entre ellos de manera que cada uno potencia las cualidades de los otros dos. El constructo resultante se caracterizó demostrando tener propiedades características que se pueden utilizar como parámetro de control durante la fabricación del mismo. Así mismo estudios in vitro del sistema desarrollado señalan que puede ser un buen candidato para el tratamiento de heridas crónicas entre otras patologías que requieran tratamientos localizados.
[CAT] Actualment, una de les majors preocupacions que permanentment llepen l'atenció dels principals sectors de la societat humana és la salut. La ciència mèdica moderna està compromesa no solament amb subministrar tractaments adequats, sinó més aviat oferir solucions efectives i específiques per a cada tipus de malaltia o patologia humana. En aquest sentit, estratègies innovadores com l'enginyeria de teixits o la medicina regenerativa, els sistemes d'alliberament controlat de fàrmacs i les nanomedicines, sorgeixen com a bones alternatives per a abordar situacions difícils de resoldre aplicant els tractaments i estratègies terapèutiques convencionals, com és el cas quan es fa necessari reemplaçar teixits o fins i tot òrgans danyats per algun traumatisme o malaltia. Concretament, el present treball de recerca té per objectiu principal dissenyar un sistema combinat per a l'alliberament controlat, estable i localitzada d'agents terapèutics que seguen capaços d'exercir el seu efecte de forma selectiva sobre la zona que amirita el tractament. Aquest constructe tindrà la versatilitat suficient com per a poder adaptar-se a quasi qualsevol tipus de tractament, des del càncer fins a la regeneració de teixit, sempre que el requisit clau del tractament sega la necessitat de subministrar el tractament de manera localitzada, estable i controlada. Per a efectes de facilitar la compressió i el disseny del sistema es va escollir per a la prova de concepte materials i fàrmacs associats a la regeneració de teixits, com a tractament per a casos de ferides cròniques. El sistema en qüestió està constituït per tres elements principals: 1) El primer element són els conjugats polimèrics d'agents terapèutics que contribuiran a augmentar la selectivitat de l'acció terapèutica del fàrmac, així com també a millora l'estabilitat, biodisponibilitat i biocompatibilitat dels mateixos. En cas que el fàrmac sega hidrofòbic, la conjugació contribueix a augmentar la seua solubilitat en aigua, i en el cas d'usar proteïnes com a agents terapèutics, la conjugació contribueix a disminuir la resposta immunològica del cos incrementant les possibilitat d'èxit del tractament. 2) El segon element són microparticles polimèriques biodegradables, que en aquest cas actuen amb agents d'encapsulació per als conjugats polimèrics, permetent així comptar amb un segon punt de control en la cinètica d'alliberament de l'agent terapèutics. Simultàniament, les microparticles també compleixen un paper de texturitzant del constructe final, adjudicant-li propietats mecànica i fisicoquímiques que contribueixen a millorar la propietats biològiques del material final, com són l'afinitat, l'adhesió i la proliferació cel·lular. 3) El tercer element consisteix en una membrana polimèrica biodegradable nanoporosa feta per electrospinning, que constitueixen el element unificats del sistema, aporta manejabilitat al constructe i és en si mateix el ultimi punt de control en la cinètica d'alliberament de l'agent terapèutic. Aquest últim ha de ser biocompatible i estable en condicions ambientals, ja que probablement aquest exposat a l'ambient mentre protegeix la ferida, en el cas concret d'aquest tipus d'aplicació. Aquests tres elements que en si mateixos constitueixen sistemes complexos per separat, s'han combinat sistemàticament per a aconseguir una relació sinergètica entre ells de manera que cadascun potencia les qualitats dels altres dos. El constructe resultant es va caracteritzar demostrant tenir propietats característiques que es poden utilitzar com a paràmetre de control durant la fabricació del mateix. Així mateix estudis in vitro del sistema desenvolupat assenyalen que pot ser un bon candidat per al tractament de ferides cròniques entre altres patologies que requeriren tractaments localitzats.
Rodríguez Escalona, GDJ. (2016). DEVELOPMENT OF CONTROLLED DRUG DELIVERY SYSTEMS OF POLYMERIC NANOMEDICINES ASSOCIATED TO SCAFFOLDS FOR TISSUE REGENERATION [Tesis doctoral no publicada]. Universitat Politècnica de València. https://doi.org/10.4995/Thesis/10251/63231
TESIS
Daniel, Karen D. "An implantable device for localized drug delivery and sensing." Thesis, Massachusetts Institute of Technology, 2009. http://hdl.handle.net/1721.1/46608.
Повний текст джерелаIncludes bibliographical references (p. 117-120).
There are many potential clinical applications for localized drug delivery and sensing systems, such as cancer, vaccinations, pain management, and hormone therapy. Localized drug delivery systems reduce the amount of drug required for a therapeutic effect and the severity of side effects. Delivery of multiple chemicals has been demonstrated previously from a polymeric microreservoir device. This dime-sized device contains small reservoirs loaded with drug and separated from the outside environment by a degradable polymer membrane. This device was modified to allow minimally invasive implantation with a large-bore needle and has demonstrated in vitro pulsatile release of a model compound after a mock implantation step. A biodegradable sealing method was developed for the polymeric microreservoir device, which makes the device completely resorbable and eliminates the surgical removal step needed with a non-resorbable device. Localized sensing systems will allow early detection of diseases and provide a tool for developing personalized treatment programs. The polymer microchip platform has been combined with magnetic relaxation switch (MRSw) nanoparticle sensors to create an in vivo sensing device. MRSw are magnetic nanoparticles (iron oxide core, crosslinked dextran shell) that can detect a variety of analytes. MRSw are kept in the device by a molecular weight cut-off (MWCO) membrane which allows analytes free access to the nanoparticle sensors.
(cont.) The MRSw aggregate in the presence of the analyte they were designed to detect and this aggregation causes a decrease in the transverse relaxation time (T2), which can be detected with magnetic resonance imaging (MRI) or nuclear magnetic resonance relaxometry. In vitro sensing experiments were used to optimize the device design and characterize its performance. In vivo device-based sensing of hCG, a soluble biomarker that is elevated in testicular and ovarian cancer, has been demonstrated. Cell lines secreting hCG were used to produce ectopic tumors in nude mice. The sensing device was implanted and magnetic resonance imaging (MRI) quantified a T2 decrease in mice with tumors compared to control mice (no tumors). This device may be the first continuous monitoring device for cancer that can be implanted at the tumor site and demonstrates feasibility of MRSw measurements in vivo.
by Karen D. Daniel.
Ph.D.
Merritt, Sonia Raquel. "Improving surgical efficacy via localized anti-proliferative drug delivery." Case Western Reserve University School of Graduate Studies / OhioLINK, 2014. http://rave.ohiolink.edu/etdc/view?acc_num=case1402017214.
Повний текст джерелаMulamba, Peter. "Biomaterials Modeling Of Localized Hyperthermia And Drug Delivery For Breast Cancer." The Ohio State University, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=osu1229981884.
Повний текст джерелаMulamba, Peter. "Biomaterials modeling of localized hyperthermia and drug delivery for breast cancer." Columbus, Ohio : Ohio State University, 2009. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1229981884.
Повний текст джерелаWilliams, Eva Christabel. "Smart Packaging: A Novel Technique For Localized Drug Delivery For Ovarian Cancer." Scholar Commons, 2012. http://scholarcommons.usf.edu/etd/4257.
Повний текст джерелаLeach, Jeffrey Harold. "Magnetic Targeted Drug Delivery." Thesis, Virginia Tech, 2003. http://hdl.handle.net/10919/31261.
Повний текст джерелаMaster of Science
Nikam, Shantanu P. "LOCALIZED ANTIBIOTIC DELIVERY VIA VALINE BASED POLY(ESTER UREA)." University of Akron / OhioLINK, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=akron1522931095020122.
Повний текст джерелаHo, Duc Hong Linh 1978. "Packaging for a drug delivery microelectromechanical system." Thesis, Massachusetts Institute of Technology, 2005. http://hdl.handle.net/1721.1/30262.
Повний текст джерелаIncludes bibliographical references (p. 52-55).
Local drug delivery is a fast expanding field, and has been a center of attention for researchers in medicine in the last decade. Its advantages over systemic drug delivery are clear in cancer therapy, with localized tumors. A silicon microelectromechanical drug delivery device was fabricated for the purpose of delivering chemotherapeutic agents such-as carmustine, a potent brain cancer drug, directly to the site of the tumor. Limitations in the delivery capacity of the device led to the design of a new package. This package is made from thermally bonded Pyrex® 7740 frames that are anodically bonded to the drug delivery chip. It increases the capacity of the chip, is smaller than the previous package and possesses true hermeticity, because of the bonding processes involved. This work describes the fabrication steps of the new package and a problem with the thermal bonding of Pyrex® frames preventing the achievement of a package true to the original design. A temporary solution was devised and the completed package was tested with regards to its intended goals. It managed to increase the load capacity of the chip by a, factor of 10, with potential for more, while decreasing the overall size of the package. Short-term hermeticity was achieved for this package by using a UV-cured epoxy to bond some pieces, which was not in the original design. Future work will focus on finding a permanent solution to the aforementioned problem, and directions for it were suggested.
by Hong Linh Ho Duc.
S.M.
Dyer, Robert J. (Robert Joseph) 1977. "Needle-less injection system for drug delivery." Thesis, Massachusetts Institute of Technology, 2003. http://hdl.handle.net/1721.1/89388.
Повний текст джерелаBright, Anne M. "Towards an improved ocular drug delivery system." Thesis, Aston University, 1992. http://publications.aston.ac.uk/9801/.
Повний текст джерелаBajpayee, Ambika Goel. "Charge-based transport and drug delivery into cartilage for localized treatment of degenerative joint diseases." Thesis, Massachusetts Institute of Technology, 2015. http://hdl.handle.net/1721.1/97832.
Повний текст джерелаCataloged from PDF version of thesis. "February 2015."
Includes bibliographical references.
Traumatic joint injuries significantly increase synovial fluid levels of pro-inflammatory cytokines that can initiate cartilage degeneration leading to osteoarthritis (OA). Articular cartilage is a highly negatively charged, avascular tissue, which relies on synovial fluid convection and electro-diffusion to transport proteins and therapeutics to tissue chondrocytes. No OA drug has yet passed the safety criteria of clinical trials due to ineffective intra-articular (i.a.) delivery methods, which require very high drug doses that cause systemic toxicity. There is a need to design local delivery mechanisms that can enable drugs or drug carriers to rapidly diffuse into the cartilage extracellular matrix to achieve intratissue therapeutic levels before these drugs are cleared from the joint space via lymphatics and synovium vasculature. This dissertation investigates the effects of size and charge of solutes on their penetration, binding and retention within negatively charged tissues such as cartilage. Based on this understanding we selected Avidin, a globular protein, as a drug carrier owing to its optimal size and high positive charge (66,000 Da, pI 10.5). Avidin resulted in a six-fold upward Donnan partitioning factor at the synovial fluid-cartilage interface, had a 400-fold higher uptake than its electrically neutral counterpart (Neutravidin), and remained bound within cartilage for at least 15 days. Competitive binding experiments revealed that despite Avidin's weak and reversible ionic binding (dissociation constant, KD ~150 [mu]M) to the negatively charged glycosaminoglycans, its long term retention was facilitated by large intratissue binding site density (NT ~ 2,920 [mu]M). Thus, structures like Avidin are ideal candidates for local i.a. drug delivery into cartilage. In vivo animal studies revealed that Avidin retained inside the joint space for extended time periods resulting half-life of 154h in rabbit cartilage which was 5-6 times longer than that in the thinner rat cartilage. This was confirmed to be consistent with the concept that diffusion-binding kinetics scale as the square of tissue thickness, emphasizing the necessity of using larger animal models for studying joint space transport and pharmacokinetics. Avidin's neutral counterpart (Neutravidin) was completely cleared from the joint space of both rats and rabbits within 24h. We then conjugated Avidin with the glucocorticoid, dexamethasone, using chemical linkers to enable its sustained release. Avidin delivered dexamethasone into cartilage deep zones where majority of chondrocytes reside thereby successfully inhibiting cytokine-induced catabolic activity in cartilage explants in-vitro. A single i.a. injection of Avidin-conjugated drug can thereby enable sustained drug delivery in low doses and therefore has the potential to replace the current clinical practice of using multiple injections of high dose glucocorticoids in patients. The biological efficacy of this system in rescuing degenerative mechanisms of OA is currently being validated in a well-accepted rabbit model of post-traumatic OA as part of a preclinical study.
by Ambika Goel Bajpayee.
Ph. D.
Oliva, Jorge Nuria. "Localized and disease-selective drug delivery using adhesive hydrogels for treatment of locally advanced TNBC." Thesis, Massachusetts Institute of Technology, 2016. http://hdl.handle.net/1721.1/104611.
Повний текст джерелаCataloged from PDF version of thesis.
Includes bibliographical references (pages 111-117).
Triple negative breast cancer (TNBC) is an aggressive form of cancer that represents 20% of invasive breast cancers, and about 15% are locally advanced at time of presentation. TNBC is negative for estrogen and progesterone receptor, as well as for HER2, and hence it is not treatable with common endocrine treatment such as tamoxifen or Herceptin. Systemic neoadjuvant therapy has been established as the preferred therapeutic approach for locally advanced breast cancer, downstaging the disease and preventing mastectomy. However, complications of systemic chemotherapy are devastating. Local therapy would prevent high concentrations of circulating drug and reduce off-target tissue retention. Yet, the means to attain ideal release kinetics and selective uptake remain elusive. I developed a novel class of biocompatible and biodegradable adhesive materials based on dendrimer and dextran that can coat the tumor and locally release doxorubicin in a controlled manner. Doxorubicin was conjugated to the dendritic component of the adhesive hydrogel to form a pro-drug capable of being released over time as the hydrogel degrades at a pre-programmed rate. The pro-drug was further modified with a ligand capable of sensing and discerning between healthy and cancer cells and facilitating uptake through receptor-mediated endocytosis (RME). The platform developed herein provides a paradigm shift in the way we treat cancer, in a local, selective and targeted manner, to impart optimal clinical outcome.
by Nuria Oliva Jorge.
Ph. D.
Birudaraj, Kondamraj. "Transbuccal drug delivery: In vitro characterization of transport pathway of buspirone and bioadhesive drug delivery system." Scholarly Commons, 2001. https://scholarlycommons.pacific.edu/uop_etds/2733.
Повний текст джерелаWarrilow, Philip A. D. "Polyamine conjugates as a potential drug delivery system." Thesis, University of Leicester, 1997. http://hdl.handle.net/2381/30012.
Повний текст джерелаBosworth, Mark Erwin. "Evaluation of liposomes as a drug delivery system /." Ann Arbor : University Microfilms International, 1987. http://www.gbv.de/dms/bs/toc/016141032.pdf.
Повний текст джерелаSaeed, Aram Omer. "Toward advanced modular drug and gene delivery system." Thesis, University of Nottingham, 2010. http://eprints.nottingham.ac.uk/27632/.
Повний текст джерелаBlackwell, Lisa Jane. "Sporopollenin exines as a novel drug delivery system." Thesis, University of Hull, 2007. http://hydra.hull.ac.uk/resources/hull:7162.
Повний текст джерелаLee, Yan Sim. "The development of controlled-chemotherapy drug delivery system." Thesis, University of Bath, 2009. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.512304.
Повний текст джерелаSalvage, Jonathan Peter. "A novel phosphorylcholine-based nanoparticulate drug delivery system." Thesis, University of Brighton, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.499068.
Повний текст джерелаPillai, Jonathan Devasitham. "Biodegradable Polymer Constructs for Disease-specific, Localized and Sustained Drug Delivery of a Novel Synthetic Curcumin Analog." The Ohio State University, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=osu1217548715.
Повний текст джерелаNguyen, Thi Lam Uyen Nguyen Centre for Advanced Macromolecular Design Faculty of Engineering UNSW. "Crosslinked microspheres as drug delivery system for liver cancer." Publisher:University of New South Wales. Centre for Advanced Macromolecular Design, 2008. http://handle.unsw.edu.au/1959.4/41528.
Повний текст джерелаRoxhed, Niclas. "A Fully Integrated Microneedle-based Transdermal Drug Delivery System." Doctoral thesis, Stockholm : Kungliga Tekniska högskolan, 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-4484.
Повний текст джерелаFreddi, Matthew James. "Intra-articular depot forming drug delivery system for osteoarthritis." Thesis, University of Nottingham, 2012. http://eprints.nottingham.ac.uk/12662/.
Повний текст джерелаGoettsche, Thorsten [Verfasser], Roland [Akademischer Betreuer] Zengerle, and Gerald A. [Akademischer Betreuer] Urban. "IntelliDrug - controlled, oral drug delivery system as tooth implant." Freiburg : Universität, 2016. http://d-nb.info/1128574195/34.
Повний текст джерелаBabu, Kavitha Mary Vadakkel. "The Development of a Novel Controlled Release Drug Delivery System." The University of Waikato, 2007. http://hdl.handle.net/10289/2590.
Повний текст джерелаHemond, Brian D. (Brian David Thomson). "A Lorentz-force actuated controllable needle-free drug delivery system." Thesis, Massachusetts Institute of Technology, 2004. http://hdl.handle.net/1721.1/37201.
Повний текст джерелаIncludes bibliographical references (leaves 89-90).
The advantages of delivering injections via needle-free methods are numerous. However, conventional methods for needle-free injection lack sufficient control over depth of penetration and shape of injection. Thus, a needle-free injector was designed, constructed, and tested, using a controllable linear Lorentz-force actuator. This actuator allows rapid control of the injection pressure during injections. Using this device, precise control over delivery parameters can be achieved. In addition, several portable power systems for this injector were developed, allowing the energy-intensive needle-free injector to be used in the field. The injector design was tested for repeatability and use for both in-vitro and in-vivo testing on murine tissue using a bacterial collagenase.
by Brian D. Hemond.
M.Eng.
S.B.
Venugopal, Balaji. "Preclinical evaluation of a novel drug delivery system for cisplatin." Thesis, University of Glasgow, 2012. http://theses.gla.ac.uk/4198/.
Повний текст джерелаGilbert, Helena Rosalind Petra. "Bioresponsive polymer-protection conjugates as a unimolecular drug delivery system." Thesis, Cardiff University, 2007. http://orca.cf.ac.uk/55685/.
Повний текст джерелаAbdulrazzaq, Fadi. "Aquasomes as a drug delivery system for proteins and peptides." Thesis, Aston University, 2016. http://publications.aston.ac.uk/30080/.
Повний текст джерелаBeier, Anne Mette. "Chitosan microparticles as a drug delivery system for protein vaccines /." [Cph.] : Pharmexa A/S : Department of Pharmaceutics, The Royal Danish School of Pharmacy, 2002. http://www.dfh.dk/phd/defences/annemettebeier.htm.
Повний текст джерелаShojaei, Amir Hossein. "Buccal mucoadhesive delivery system of acyclovir." Scholarly Commons, 1997. https://scholarlycommons.pacific.edu/uop_etds/2626.
Повний текст джерелаYang, Xiaojuan. "Development of Nanoparticle Systems for Therapeutic Drug Delivery." The Ohio State University, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=osu1248972068.
Повний текст джерелаChinnakavanam, Sundararaj Sharath Kumar. "Development of a Multilayered Association Polymer System for Sequential Drug Delivery." UKnowledge, 2013. http://uknowledge.uky.edu/cbme_etds/13.
Повний текст джерелаWong, Ling Wai. "Molecular delivery system based on the nanoporous zeolite microstructures /." View abstract or full-text, 2006. http://library.ust.hk/cgi/db/thesis.pl?BIEN%202006%20WONG.
Повний текст джерелаLee, Wang Wang. "Factors affecting drug release and absorption from a novel oral delayed release drug delivery system." Thesis, Durham University, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.269886.
Повний текст джерелаVenthoye, M. Geraldine. "Characterisation of an amorphous dry powder aerosol system." Thesis, University College London (University of London), 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.265519.
Повний текст джерелаHawley, Ann Elizabeth. "The uptake of nanospheres by the lymphatic system." Thesis, University of Nottingham, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.307765.
Повний текст джерелаSvirskis, Darren. "Development of a novel drug delivery system based on conducting polymers." Thesis, University of Auckland, 2010. http://hdl.handle.net/2292/6568.
Повний текст джерелаCheng, Erik Ho Yan. "Combination of hydrogel and liposomes as a responsive drug delivery system." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp01/MQ29374.pdf.
Повний текст джерелаNASCIMENTO, Débora Dolores Souza da Silva. "Obtenção de drug delivery system carbamazepina-zif-8 visando liberação prolongada." Universidade Federal de Pernambuco, 2017. https://repositorio.ufpe.br/handle/123456789/25939.
Повний текст джерелаApproved for entry into archive by Alice Araujo (alice.caraujo@ufpe.br) on 2018-08-28T18:14:14Z (GMT) No. of bitstreams: 2 license_rdf: 811 bytes, checksum: e39d27027a6cc9cb039ad269a5db8e34 (MD5) DISSERTAÇÃO Débora Dolores Nascimento.pdf: 3594688 bytes, checksum: cdf7df39006953035bd1e74095fb8d37 (MD5)
Made available in DSpace on 2018-08-28T18:14:15Z (GMT). No. of bitstreams: 2 license_rdf: 811 bytes, checksum: e39d27027a6cc9cb039ad269a5db8e34 (MD5) DISSERTAÇÃO Débora Dolores Nascimento.pdf: 3594688 bytes, checksum: cdf7df39006953035bd1e74095fb8d37 (MD5) Previous issue date: 2017-05-26
FACEPE
A carbamazepina (CBZ) é um derivado tricíclico do iminoestilbeno com atividade farmacológica antiepiléptica. Entre os problemas deste fármaco está a sua autoindução com a necessidade de administração de até 4 vezes por dia, além da alta incidência de reações adversas, o que provavelmente está relacionado com a sua baixa solubilidade, visto que pertence à classificação biofarmacêutica de classe II. Dessa maneira, a tecnologia farmacêutica auxilia na redução de alguns desses problemas como, por exemplo, através da adsorção da CBZ a um excipiente inovador para que auxilia com a sua solubilidade e altere sua liberação, modulando e prolongando a dissolução do fármaco. Assim, esse trabalho objetivou desenvolver e caracterizar sistemas formados entre a CBZ e uma estrutura organometálica chamada ZIF-8, com a finalidade de ser empregada nos estudos de pré-formulação de forma farmacêutica de liberação prolongada para o tratamento da epilepsia. Os sistemas foram obtidos após agitação do fármaco e da ZIF-8 em diferentes solventes (metanol, etanol, e etanol:H₂O 61%) e proporções molares para que fosse escolhido o melhor meio reacional, através da melhor eficiência de incorporação. As caracterizações dos sistemas desenvolvidos foram realizadas, em seguida, através várias técnicas analíticas para assegurar a obtenção do sistema, procedendo com os ensaios de dissolução in vitro sob condições sink para verificar o comportamento da liberação da CBZ quando adsorvido à ZIF-8 em diferentes pH’s e em meios com presença e ausência de tensoativo. Os perfis de dissolução foram analisados através da área sob a curva (AUC), eficiência de dissolução (ED%), modelo-independente através do fator de similaridade (ƒ2). Por meio do método desenvolvido o escolhido para obtenção foi o realizado com etanol:H₂O 61% como solvente, na proporção molar 1:1 após 3 horas de agitação sem intervalos. Através das análises térmicas pode-se comprovar a obtenção do sistema, indicando que o mesmo também pode influenciar positivamente na estabilidade térmica do fármaco. Os espectros de FT-IR, difratogramas de DR-X e demais análises realizadas, corroboraram com os resultados, confirmando a formação do sistema CBZ-ZIF-8. O estudo de dissolução possibilitou verificar modulação da liberação do fármaco independente do pH utilizado, obtendo resultados de uma liberação máxima de 36,2% em pH 1,2 com 1% de lauril sulfato de sódio (LSS), contra 17,7%, 12,5% e 11,2% quando submetido aos meios sem LSS, com pH 1,2, pH 4,5 e pH 7,6, respectivamente, durante o período de 24 horas. O presente trabalho através dos resultados de liberação prolongada independente de pH, trouxe informações relevantes para o desenvolvimento de formas farmacêuticas de liberação modificada que utilize CBZ como insumo farmacêutico ativo.
Carbamazepine (CBZ) is a tricyclic derivative of iminostilbene with pharmacological antiepileptic activity. Among the problems of this drug is its self-induction with the need to administer up to 4 times a day, in addition to the high incidence of adverse reactions, which is probably related to its low solubility, since it belongs to the class II biopharmaceutical classification. Thus, pharmaceutical technology assists in the reduction of some of these problems, for example by adsorbing CBZ to an innovative excipient, which assists with its solubility and alters its release, modulating and prolonging the dissolution of the drug. Thus, this work aimed to develop and characterize systems formed between CBZ and an organometallic structure called ZIF-8, with the purpose of being used in the preformulation studies of pharmaceutical form of extended release for the treatment of epilepsy. The systems were obtained after agitation of the drug and ZIF-8 in different solvents (methanol, ethanol, and ethanol: H₂O 61%) and molar ratios to the best reaction medium chosen, through the best incorporation efficiency. The characterization of the developed systems was then performed through several analytical techniques to ensure the system was obtained, proceeding with the in vitro dissolution tests under sink conditions to verify the CBZ release behavior when adsorbed to ZIF-8 at different pH's And in media with presence and absence of surfactant. The dissolution profiles were analyzed through the area under the curve (AUC), dissolution efficiency (ED%), model-independent through the similarity factor (ƒ2). Using the developed method the chosen one was obtained with ethanol: H₂O 61% as solvent, in the 1: 1 molar ratio after 3 hours of agitation without intervals. Through the thermal analysis, it is possible to prove the system, indicating that it can also positively influence the thermal stability of the drug. The FT-IR spectra, DR-X diffractograms and other analyzes, corroborated the results, confirming the formation of the CBZ-ZIF-8 system. The dissolution study allowed to verify the modulation of the drug release independent of the pH used, obtaining results of a maximum release of 36.2% in pH 1.2 with 1% of sodium lauryl sulfate (LSS), against 17.7% 12.5% and 11.2% when submitted to the media without LSS, with pH 1.2, pH 4.5 and pH 7.6, respectively, during the 24 hour period. The present work through the results of independent release of pH, has brought important information for the development of pharmaceutical forms of modified release that uses CBZ as active pharmaceutical ingredient.
Al, Thaher Yazan. "Antimicrobial drug LbL-assembled delivery system for orthopaedic nanocomposite bone cements." Thesis, Cardiff University, 2018. http://orca.cf.ac.uk/112718/.
Повний текст джерелаGaspar, Diana Patrícia Rodrigues. "Novel strategy to produce a drug delivery system for skin regeneration." Master's thesis, Universidade da Beira Interior, 2012. http://hdl.handle.net/10400.6/1118.
Повний текст джерелаAs lesões na pele são acontecimentos traumáticos que levam ao aumento da perda de fluidos, a infecções, à formação de cicatrizes e ao aparecimento de regiões imunocomprometidas. Estas feridas podem ser causadas por desordens de origem genética, traumas ou mesmo devido a cirurgias. Deste modo, uma área substancial da pele pode ser danificada, muitas vezes sem a possibilidade de regeneração. Os investigadores têm procurado desenvolver novos sistemas de entrega de drogas, de forma a acelerar o processo de cicatrização. O microencapsulamento celular surgiu recentemente como uma nova abordagem, para entrega controlada e de longa duração de agentes terapêuticos produzidos e secretados pelas próprias células, tais como componentes da matriz extracelular e factores de crescimento, os quais são essenciais para a regeneração. Esta tecnologia tem por base a imobilização de células, dentro de uma matriz polimérica rodeada por uma membrana semi-permeável. Assim, as células não são reconhecidas pelo sistema imunitário do hospedeiro e a membrana permite a difusão de nutrientes e gases para o interior da matriz e a saída das moléculas bioactivas secretadas pelas células e dos resíduos resultantes do metabolismo celular. No entanto, a terapia celular necessita ainda de ser optimizada. O alginato é um polímero que tem sido usado para o encapsulamento celular, devido ao seu fácil processo de gelificação, excelente biocompatibilidade, biodegradabilidade e estabilidade in vivo. Por outro lado, os sistemas nanoparticulados têm sido amplamente utilizados em aplicações biomédicas, por exemplo na produção de dispositivos de entrega direcionada de moléculas bioactivas, uma vez que permitem obter um perfil de libertação controlado. O presente trabalho teve como objectivo o desenvolvimento de micropartículas de alginato para encapsular fibroblastos humanos e nanopartículas de quitosano, com o intuito de futuramente serem usadas como agentes promotores da cicatrização de feridas. Inicialmente, foram produzidos dois tipos de micropartículas, um à base de alginato e outro de alginato com colagénio. As micropartículas produzidas foram caracterizadas quanto ao seu tamanho e geometria por microscopia electrónica de varrimento. Posteriormente, foram também adquiridas imagens de confocal para confirmar o encapsulamento de células nas micropartículas. O perfil citotóxico dos transportadores foi caracterizado através de testes de viabilidade celular, os quais confirmaram a biocompatibilidade dos transportadores. O perfil de libertação das células foi observado por análise microscópica ao longo dos dias. Numa segunda parte do trabalho foram produzidas nanopartículas de quitosano com o objetivo de serem incorporadas nas micropartículas como transportadores de factores de crescimento e, assim, favorecer a cicatrização das feridas. A eficiência de encapsulação das nanopartículas foi avaliada através da incorporação de uma proteína modelo, albumina de soro bovino. Posteriormente fez-se a caracterização da morfologia e do tamanho destas nanopartículas. Os estudos efectuados demonstraram que o sistema desenvolvido é adequado para a libertação de células e moléculas bioativas de forma controlada, prolongada e em concentrações fisiológicas.
Zahedi, Payam. "Sustained Intraperitoneal Chemotherapy via an Injectable Depot Delivery System for the Treatment of Ovarian Cancer." Thesis, 2012. http://hdl.handle.net/1807/32857.
Повний текст джерелаChen, Pen-Chung. "Polymeric drug delivery systems lidocaine microspheres for prolonged and localized in vivo anesthetic effects and light-induced drug release from polymeric device mediated by bacteriorhodopsin." 2004. http://catalog.hathitrust.org/api/volumes/oclc/68945574.html.
Повний текст джерелаTaite, Lakeshia J. "Biocompatible copolymers for localized cardiovascular drug delivery and tissue engineering." Thesis, 2005. http://hdl.handle.net/1911/18983.
Повний текст джерелаTzuHui, HUANG, and 黃資惠. "Localized Two Steps Controlled Released Microneedle Patch for Transdermal Drug Delivery." Thesis, 2013. http://ndltd.ncl.edu.tw/handle/53948602792555668750.
Повний текст джерела國立清華大學
奈米工程與微系統研究所
101
Hyperpigmentation is a hypermelanosis occurring in all skin types and results from the overproduction of melanin or an irregular dispersion of pigment after cutaneous inflammation. Patients with hyperpigmentation can have a significant psychosocial impact on skin-of-color patients, including Asian. There are a variety of medications and procedures added to photoprotection cream that can safely and effectively treat hyperpigmentation. A fixed triple combination cream, containing 4% Hydroquinone (HQ), 0.05% Tretinoin (Vit. A acid), and 0.01% fluocinolone acetonide (steroids), called Tri-Luma from Galderma Laboratories (Fort Worth, TX), offer maximal efficacy for clinical trial. HQ and Vit. A Acid can inhibit the formation of melanin by inhibiting the tyrosinase in melanocytes in the bottom of epidermis layer. Fluocinolone acetone, the steroids can eliminate the irritation caused by hydroquinone or tretinoin. However, clinical study showed that over 87.5% of patients were noted to have side-effects with cream treatment because of the Hydroquinone cytotoxicity and slow degradation. In this study, we proposed a new design of microneedles patch with different height for different skin layer to treat hyperpigmentation. For the deeper melanocyte in the bottom of epidermis layer, longer microneedle in the center of patch served as a fast released carrier loaded active ingredient HQ and Vit. A Acid for drug localization and fast metabolism to decrease HQ cytotoxicity. The shorter microneedle contained fluocinolone acetonide to dissolve gently in the keratinocytes layer to eliminate the irritation. In vitro and in vivo study showed the feasibility of hyperpigmentation treatment. This approach could be a potential technology enabling direct transcutaneous delivery in clinical applications.
Lipke, Elizabeth Ann. "Localized drug delivery from poly(ethylene glycol) copolymers for the prevention of restenosis." Thesis, 2005. http://hdl.handle.net/1911/18855.
Повний текст джерела